



**ANIMAL HEALTH, NUTRITION
& TECHNOLOGY INNOVATION
EUROPE**

10-12 February • London, UK
@AHInnovation #AHTNI

INNOVATION SHOWCASE FINALISTS 2025

Animal Health, Nutrition and Technology Innovation Europe is the premier investment forum showcasing the most exciting investment opportunities in animal health and nutrition. It connects those businesses with financial investors and strategic corporate partners.

allegro

ASTRA
Therapeutics

BENNO
THERAPEUTICS

eQcell
One-Health Since 2010

FABP Biotech
Animal Health

MEDEA
Biopharma

OneCup
AI

ORGANICIN
SCIENTIFIC

Peptidus
Nature knows best

RESILIENTBIOTICS

Snoretox
Ltd

STM

sylvester.ai

veheri

VEROVACCINES

VETBIOLIX
NEW ROUTE TO ANIMAL HEALTH

We are proud to announce the **16 finalist companies** selected to present at the 2025 Innovation Showcase.

Headline Partner

Elanco

Platinum Associate
Partners

**Boehringer
Ingelheim**

MSD
Animal Health

zoetis

Associate Partners

argenta

AstraSana
ANIMAL HEALTH AG

GHO
CAPITAL

provaxs

**GHENT
UNIVERSITY**

WittKieffer

WuXi Biologics
Global Solution Provider

A SPECIAL THANK YOU TO THE SELECTION COMMITTEE


The Selection Committee members were responsible for selecting the showcase companies at **Animal Health, Nutrition and Technology Innovation Europe 2025**. Each of our committee members has an extensive breadth of experience and knowledge across animal health and nutrition industries and will be available for meetings at the conference.



Philippe Moreau
Director
Animal Health Angels



Julia Stephanus
Partner
Borealis Ventures



Paul Dick
President
Paul Dick & Associates



Justine Conway
VP Business Development &
External Innovation
Elanco



Andreas Kastenbauer
Partner
MIG Capital



Natalie Marks
President
MarksDVM Consulting
& Executive Committee Member
VANE



Charles Hoare
Managing Director, Head of
European Healthcare
Stifel



Sarah Aitchison
Incubation Manager
vHive University of Surrey





INNOVATION SHOWCASE FINALISTS

PRODUCTION ANIMALS



SEED

ASTRA Therapeutics develops novel parasiticides that selectively kill parasites while passing safely through the host animals. Their primary focus is on the \$2Bn+ markets for heartworm and coccidiosis, with the potential to expand into other protozoa and worms, with their first data (in chickens) anticipated in early 2025. Their proprietary ParaX platform is the result of a decades worth of experience in the field of tubulin isolation, crystallization and atomic resolution analysis.



SEED

FABP Biotech emerged from decades of work on anti-parasitic vaccines. Their vaccine technology platform, "HelmiVax" is changing the paradigm in veterinary parasitic diseases management.

Based on an engineered recombinant protein, their drug substance is the basis for a multi-species vaccine platform against helminth infections. The first products they are developing include LiVac (demonstrated to provide >97% protection of livestock against liver fluke in challenge studies) and HeartVac (designed to protect dogs against heartworm disease)."

This is the first vaccine preventing against parasitic diseases, which today can only be treated by chemical drugs plagued by serious side effects and high costs.



SEED

OneCup AI is a pioneering provider of computer vision solutions tailored for animal care, catering to both livestock producers and pet owners. Their innovative technology enables early detection of behavioural changes in animals, allowing for proactive health management and disease prevention.

Key to their success is a patented AI pipeline that analyzes data at an impressive rate of 25 million times per day, delivering real-time insights and proactive alerts to producers. Their platform not only detects early signs of illness but also offers a visual representation of the data, empowering customers to make informed decisions about their animals' health.

By offering a subscription-based model per installed camera, they provide an invaluable service that enhances the well-being of animals while optimizing operational efficiency for our customers.



INNOVATION SHOWCASE FINALISTS

PRODUCTION ANIMALS

ORGANICIN
SCIENTIFIC

SEED

Organicin Scientific are developing the world's first bacteriocin pipeline, leveraging machine learning and extensive empirical data to optimize and validate bacteriocins efficiently. Their proprietary discovery technology platform accelerates the identification and development of effective bacteriocins for rapid commercial development.

Their first product is a bacteriocin-based shrimp feed additive designed to combat Acute Hepatopancreatic Necrosis Disease. This additive is seamlessly incorporated into shrimp feed and delivered orally, offering a practical, efficient solution for disease prevention that strengthens shrimp health, resilience, and productivity from the start.

Peptidus
Nature knows best

SEED

Peptidus is an AI-Platform for discovering New Peptide-Based Therapies for Animal Health.

Once the target of the new therapy has been identified, Peptidus platform will create "in silico" candidates that will be validated by the AI. Once the top candidates are validated, the peptide can be synthesized, and a Proof of Concept created and tested in their labs.

Compared to regular industry processes, their technology can significantly increase the success rate of the drug discovery phase of a new therapy, while reducing the time necessary for the process. Therefore, opening the possibility to develop drugs for markets not yet pursued by the pharmaceutical companies, due to the risk/return ratio been too high.

RESILIENTBIOTICS

SERIES B

Resilient Biotics is developing precision microbial products to address longstanding health challenges in animal production. The company's primary focus is the prevention of respiratory diseases through optimization of microbiome communities. Resilient's first product in development is a proprietary blend of live microorganisms delivered intranasally to cattle for prevention of bovine respiratory disease. This product has been shown to reduce lung infection in preclinical challenge studies, and is currently licensed to Axiota Animal Health.





INNOVATION SHOWCASE FINALISTS

PRODUCTION ANIMALS

STM



SEED

SingleTimeMicroneedle's 'STM Patch' is a thermally-stable multi-dose microneedle patch that is applied to the skin (belly, ear, nose, udder, etc.), and then removed, to painlessly and superficially embed an array of micron-sized microneedles. The skin closes over the tips, preventing infection and allowing the surgical suture-like polymer to degrade and deliver payloads immediately, consistently over days/weeks, or in separate doses days, weeks, or months apart. Their technology can support many types of vaccines, drugs, and supplements, allowing STM to enter multiple markets in veterinary health.

 VEROVACCINES

SERIES A

Verovaccines are a German Biotech that have developed a novel vaccine platform technology that covers all segments of the value chain from vaccine design to industrial production according to the SAME principle and is particularly suitable for livestock, but can also be used for other segments such as pets and aquaculture. The flexibility and speed of this platform is reminiscent of mRNA vaccines, but at 1/100 to 1/1,000 of the production cost.

The technology platform is characterized by very rapid vaccine development, a simple vaccine combination, cost-effective production, and the aforementioned deep platform concept. In this concept, almost the same steps are used in vaccine generation/ optimization, development and production regardless of the vaccine (so far vaccines for pigs, cattle, sheep and poultry).



COMPANION SHOWCASE FINALISTS

COMPANION FINALISTS



SEED

Founded in 2021, **Allegro** are a Belgian company with the ultimate vision to prolong life, engineering the body atom-by-atom, blending engineering and biotech. Their animal health product, Synocure consists of injectable hydrogel microparticles, built on a groundbreaking nanotechnology, which acts as an injectable biodegradable joint distractor. When injected, these particles mix with the synovial fluid, and reinforce the lost elasticity of the fluid, which is necessary for the shock absorbing potential.

Very extensive testing on myriad animal models, with phenomenal results, have brought them to a stage where we are close to commercialization.



SERIES A

Benno Therapeutics is developing a novel immunotherapy for the treatment of canine bladder cancer, a severe indication for which there is currently no available registered treatment option. Their therapy presents a new innovative vaccine strategy to tackle canine cancer that is safe without side effects, affordable and more effective than current standard therapies. By targeting the tumor blood vessels instead of the tumor itself this immunotherapy has the potential to prevent resistance development and metastasis.



SERIES A

eQcell is pioneering the use of proprietary mesenchymal stromal cells (MSCs) for treatment of osteoarthritis, inflammatory and infectious diseases in horses and companion animals (a ~\$US5.5B market and growing) for eventual translation to human therapies (a ~\$US53B market and the long-term human health investment opportunity).

Their "eQcells" are developed in closed collaboration with key thought leaders in the space to ensure products are aligned with the needs of the market.



COMPANION SHOWCASE FINALISTS

COMPANION FINALISTS



SEED

Medea Biopharma is a German biotechnology company founded in 2023, specializing in developing a new generation of natural and safe antibacterial products based on bacteriophages to address the global challenge of antibiotic resistance.

Their product combats canine bacterial infections without contributing to resistance, as well as combating multidrug resistant bacteria. These sustainable alternatives aim to replace conventional antibiotics, offering effective and environmentally friendly solutions to combat harmful bacteria.

The company has achieved remarkable milestones since founding in 2023, and were named one of Germany's top 16 startups by the German Chancellor.



SERIES A

Snoretex have created the world's first effective and long-lasting drug combating muscle weakness and BOAS syndrome. Their game-changing technology is based on tetanus toxin in tiny doses, with antibody trap technology to by-pass any anti-tetanus antibodies. Just as Botox uses tiny amounts of botulinum toxin to relax muscles, our prototype therapeutic uses minute amounts of tetanus toxin to achieve the opposite effect – muscle toning.

Snoretex are set to restore the breathing and lives of millions of Bulldogs, Pugs and similar breeds.



SEED

Sylvester.ai is a Canadian company, founded in 2020, leading visual AI species pain recognition; their first product is Tably, an API plug in for veterinary and consumer facing digital platforms, created to predict how companion cats are feeling based on subtle facial cues.

Tably allows users to take a picture/video of a cat and receive a pain assessment with over 87% accuracy and is the only digital SaaS product available to clinics to monetize the pet owner through scan packages, while also driving more medicalization of cats.

Find out more about Sylvester.ai in an interview with their CEO & Founder Susan Groeneveld [here](#).





COMPANION SHOWCASE FINALISTS

COMPANION FINALISTS

VETBIOLIX
NEW ROUTE TO ANIMAL HEALTH

SERIES B

Vetbiolix is a French veterinary biotech develop innovative products for treatment and prevention of diseases affecting Pets. With three main products (VBX-1000, VBX-2000, VBX-3000) Vetbiolix offer therapeutic treatments for canine and feline periodontitis, osteoarthritis and gut motility disorders.

The company is currently supported by VC investors CapTech Sante, Nord France Amorçage, Tudigo and BPI France.



SEED

Veheri is a cutting-edge platform in veterinary diagnostic imaging, built by vets for vets, with a vision to transform veterinary care through seamless teleradiology services and a strong educational community.

Key features include:

- Comprehensive Teleradiology Services
- Smart, User-Friendly Workspace
- AI Readiness
- Global Scalability

Veheri's Competitive Advantage lies in its unique blend of technology, expertise, and innovation, setting it apart in the veterinary diagnostic imaging market

MAKE THE RIGHT CONNECTIONS

Our Swapcard platform allows you to preschedule meetings with these exciting start-ups!

Animal Health, Nutrition and Technology Innovation Europe is committed to bringing innovative and inspiring emerging companies together with partners looking to acquire and invest.

To ensure all our attendees make the most valuable connections possible at the Summit, the **SWAPCARD** platform allows you to create a bespoke meeting schedule, ensuring you connect with the industry stakeholders that are **most important** in building your business.

SWAPCARD gives you access to the entire attendee list and allows you to message AND invite people to connect during the formal meeting sessions run throughout the day.

SCHEDULED MEETINGS

Who You Will Meet

- + Start-Ups & Early Stage Biotech Companies
- + Business Development Teams from International Pharmaceutical Companies
- + Leadership from Multinational Corporations
- + Mid to late-stage Health and Nutrition Companies
- + Global Distribution Leaders
- + Venture Capital and Private Equity Investors
- + Market Intelligence and Consultancy Providers
- + Universities and National Regulatory Bodies
- + Contract Research & Contract Manufacturing
- + Veterinary Practitioners

Join the Finalists:
REGISTER TODAY



VENUE & PRICING

VENUE InterContinental London - The O2 • London SE10 0TW

PASS TYPE	EARLY BIRD UNTIL 26 JANUARY	STANDARD RATE
Emerging Companies & Start Ups, Academics, Charities, Veterinary Practices, Angel and VC Investors For Start-Ups with under £4m in Annual Revenue Please note: Those offering consultancy or market intelligence services do not qualify for this rate	£1,299 +VAT	£1,499 +VAT
Delegate Health, Nutrition and Tech Companies (under £100m in annual revenue)	£2,699 +VAT	£2,999 +VAT
Multinationals & Service Providers CROs, CMOs, Consultants, M&A Advisors, Private Equity, Incubators, Accelerators and Distributors and Companies over £100m in annual revenue	£3,999 +VAT	£3,999 +VAT

BIG SAVINGS WITH BIG BOOKINGS

SAVE 10% - Book a team of 3+

SAVE 15% - Book a team of 5+

[REGISTER HERE](#)

Team discounts are only valid on industry rates and not in conjunction with any other offer or promotion. Payment Terms: Please note that all prices are plus VAT and a £49 processing fee will apply to any invoices requested. All Prices are in GBP. All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above. No discount offers can be combined with any other offer. Please view our Cancellation Policy. QUESTIONS? Please email events@kisacoresearch.com.